SiBone (SIBN) Stock Price, News & Analysis

Company Overview

SI-BONE, Inc. (NASDAQ: SIBN) is a commercial-stage medical device company that develops and markets minimally invasive surgical implants for stabilization and fusion of the sacroiliac (SI) joint. The company’s flagship product, the iFuse Implant System, features a series of triangular titanium implants designed to replicate the anatomy of the SI joint and promote bone ongrowth. SI-BONE’s technology is intended to reduce pain and improve function in patients suffering from SI joint dysfunction due to degenerative sacroiliitis or traumatic disruption.

Founded in 2008 and headquartered in Santa Clara, California, SI-BONE received FDA clearance for the iFuse Implant System in 2009 and launched commercial operations in the United States the following year. Building on clinical evidence and surgeon feedback, the company introduced the iFuse-3D implant in 2019, incorporating a porous 3D-printed architecture to enhance osseointegration. SI-BONE supports its implants with a comprehensive training and education program for spine and pelvic surgeons, alongside a patient registry that tracks outcomes and safety data.

In addition to its U.S. footprint, SI-BONE markets the iFuse Implant System in Europe under CE marking, as well as in selected Asia-Pacific and Australian markets. The company collaborates with leading orthopedic and neurosurgical centers to advance research on SI joint disorders and to refine surgical techniques. Ongoing studies focus on long-term clinical benefits, expanded indications and health-economic outcomes associated with SI joint fusion.

SI-BONE is led by a management team with deep expertise in orthopedics, spine surgery, and medical device commercialization. The company’s executive leadership includes professionals with backgrounds at major device manufacturers and academic medical centers. Under this leadership, SI-BONE continues to invest in product innovation, clinical evidence generation and global market expansion to address the needs of patients with chronic lower back and pelvic pain.

Key Stats

• Today's Range: $18.11 to $18.58
• 50-Day Range: $13.65 to $19.79
• 52-Week Range: $11.70 to $20.05
• Volume: 288,621 shs
• Average Volume: 394,567 shs
• Market Capitalization: $786.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.50
• Consensus Rating: Buy

SiBone Stock Analysis - MarketRank™

SiBone scored higher than 83% of companies evaluated by MarketBeat, and ranked 170th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

SiBone has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

SiBone has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for SiBone are expected to grow in the coming year, from ($0.78) to ($0.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of SiBone is -28.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of SiBone is -28.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

SiBone has a P/B Ratio of 4.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.25% of the float of SiBone has been sold short.

Short Interest Ratio / Days to Cover

SiBone has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SiBone has recently decreased by 6.45%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SiBone does not currently pay a dividend.

Dividend Growth

SiBone does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.3 / 5
• Environmental Score: -1.44

Percentage of Shares Shorted

4.25% of the float of SiBone has been sold short.

Short Interest Ratio / Days to Cover

SiBone has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SiBone has recently decreased by 6.45%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

SiBone has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for SiBone this week, compared to 3 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, SiBone insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,643,123.00 in company stock.

Percentage Held by Insiders

Only 4.00% of the stock of SiBone is held by insiders.

Percentage Held by Institutions

98.11% of the stock of SiBone is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SIBN Stock Analysis - Frequently Asked Questions

How have SIBN shares performed this year?

SiBone's stock was trading at $14.02 at the start of the year. Since then, SIBN shares have increased by 31.7% and is now trading at $18.46.

How were SiBone's earnings last quarter?

SiBone (NASDAQ:SIBN) announced its quarterly earnings results on Monday, May, 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.09. The company had revenue of $47.29 million for the quarter, compared to analyst estimates of $45.13 million. SiBone had a negative net margin of 15.03% and a negative trailing twelve-month return on equity of 16.00%.
Read the conference call transcript.

Does SiBone have any subsidiaries?

SiBone subsidiaries include SI-BONE Deutschland GmbH, SI-BONE S.R.L., and SI-BONE UK LTD.

When did SiBone IPO?

SiBone (SIBN) raised $84 million in an initial public offering on Wednesday, October 17th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

How do I buy shares of SiBone?

Shares of SIBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SiBone own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SiBone investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Humana (HUM), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 5/05/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:SIBN
• CIK: 1459839
• Web: www.si-bone.com
• Phone: (408) 207-0700
• Fax: N/A
• Employees: 350
• Year Founded: 2008

Price Target and Rating

• Average Stock Price Target: $22.50
• High Stock Price Target: $25.00
• Low Stock Price Target: $19.00
• Potential Upside/Downside: +21.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.91 million
• Net Margins: -15.03%
• Pretax Margin: -15.03%
• Return on Equity: -16.00%
• Return on Assets: -11.69%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 8.53
• Quick Ratio: 7.26

Sales & Book Value

• Annual Sales: $167.18 million
• Price / Sales: 4.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.98 per share
• Price / Book: 4.64

Miscellaneous

• Outstanding Shares: 42,620,000
• Free Float: 40,910,000
• Market Cap: $786.77 million
• Optionable: Optionable
• Beta: 0.93